SNGX - Soligenix reports 100% protection using a bivalent thermostabilized filovirus vaccine

Soligenix (NASDAQ:SNGX) announces 100% protection of non-human primates (NHPs) against lethal Sudan ebolavirus challenge using a bivalent, thermostabilized vaccine formulated in a single vial, reconstituted only with water immediately prior to use. This is part of an ongoing collaboration with the University of Hawai?i at M?noa, demonstrating the successful presentation of one or more antigen(s) within the same formulation while maintaining full potency and thermostability. It further demonstrates the broad applicability of the vaccine platform, and its potential role in the U.S. government's initiative for pandemic preparedness. This same heat stable vaccine platform has also been applied to the development of a COVID-19 vaccine, CiVax, which the Company anticipates testing against the new omicron variant, having shown immunogenicity against previous variants including delta.

For further details see:

Soligenix reports 100% protection using a bivalent thermostabilized filovirus vaccine